Investors + Media

Webcast ImageWebcast
AveXis, Inc. Conference Call to Discuss Type 2 Program Update (Replay)
12/13/17 at 4:30 p.m. ET
AveXis, Inc. Conference Call to Discuss Type 2 Program Update
Wednesday, December 13, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1, we also intend to expand the study of gene therapy into SMA Type 2 and two additional rare neurological monogenic disorders: Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.

Recent News

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
AveXis Reports Third Quarter 2017 Financial and Operating Results
AveXis to Report Third Quarter 2017 Financial and Operating Results

Upcoming Events

There are currently no events scheduled.


Sign up to receive e-mail alerts whenever AveXis, Inc. posts new information to the site. Just enter your e-mail address and click Submit.


Jim Goff
Vice President, Investor Relations and Corporate Communications
Phone: (650) 862-4134

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet